A

Aclaris Therapeutics
D

ACRS

2.24000
USD
-0.08
(-3.45%)
مغلق
حجم التداول
15,595
الربح لكل سهم
-1
العائد الربحي
-
P/E
-4
حجم السوق
239,721,966
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ADCT
    -0.04000
    (-2.40%)
    1.63000 USD
    A
    AGEN
    -0.11500
    (-3.34%)
    3.33000 USD
    A
    ALXO
    -0.01000
    (-0.89%)
    1.11500 USD
    AMGN
    AMGN
    5.10
    (1.71%)
    303.15 USD
    A
    ASMB
    -0.180
    (-1.44%)
    12.360 USD
    B
    BCRX
    -0.17000
    (-1.81%)
    9.20000 USD
    BIIB
    BIIB
    3.560
    (2.60%)
    140.630 USD
    B
    BPMC
    -2.080
    (-2.20%)
    92.280 USD
    C
    CRSP
    -2.620
    (-5.19%)
    47.840 USD
    GILD
    GILD
    -0.140
    (-0.13%)
    109.920 USD
    I
    INCY
    0.790
    (1.11%)
    72.150 USD
    MRK
    MRK
    1.820
    (2.08%)
    89.500 USD
    N
    NKTR
    -0.02600
    (-2.72%)
    0.93130 USD
    NVS
    NVS
    2.100
    (1.96%)
    109.370 USD
    P
    PTCT
    0.300
    (0.60%)
    50.680 USD
    المزيد
الأخبار
المقالات

العنوان: Aclaris Therapeutics

القطاع: Healthcare
الصناعة: Diagnostics & Research
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; andATI-1777.